Amedisys, Inc. (NASDAQ: AMED) Stock Competitors & Peer Comparison
See AMED's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMED and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMED | $100.99 | +0.01% | 3.3B | 39.30 | $2.57 | N/A |
| HCA | $382.19 | +1.51% | 84.8B | 13.20 | $28.96 | +0.78% |
| THC | $233.20 | +17.17% | 20.1B | 13.53 | $17.24 | N/A |
| DVA | $235.44 | +0.50% | 15.1B | 20.06 | $11.73 | N/A |
| SOLV | $78.01 | +1.00% | 13.5B | 12.50 | $6.24 | N/A |
| FMS | $24.59 | +0.61% | 13.2B | 9.76 | $2.52 | +3.52% |
| EHC | $112.89 | +1.65% | 11.2B | 19.83 | $5.69 | +0.67% |
| ENSG | $172.99 | +3.27% | 10.1B | 25.07 | $6.90 | +0.15% |
| UHS | $155.75 | +2.96% | 9.8B | 6.91 | $22.54 | +0.51% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
HCA Healthcare, Inc. (NYSE: HCA)
AMED vs HCA Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, HCA has a market cap of 84.8B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while HCA trades at $382.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas HCA's P/E ratio is 13.20. In terms of profitability, AMED's ROE is +0.11%, compared to HCA's ROE of -1.54%. Regarding short-term risk, AMED is less volatile compared to HCA. This indicates lower risk in terms of short-term price fluctuations for AMED.Check HCA's competition here
Tenet Healthcare Corporation (NYSE: THC)
AMED vs THC Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, THC has a market cap of 20.1B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while THC trades at $233.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas THC's P/E ratio is 13.53. In terms of profitability, AMED's ROE is +0.11%, compared to THC's ROE of +0.38%. Regarding short-term risk, AMED is less volatile compared to THC. This indicates lower risk in terms of short-term price fluctuations for AMED.Check THC's competition here
DaVita Inc. (NYSE: DVA)
AMED vs DVA Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, DVA has a market cap of 15.1B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while DVA trades at $235.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas DVA's P/E ratio is 20.06. In terms of profitability, AMED's ROE is +0.11%, compared to DVA's ROE of -1.33%. Regarding short-term risk, AMED is less volatile compared to DVA. This indicates lower risk in terms of short-term price fluctuations for AMED.Check DVA's competition here
Solventum Corporation (NYSE: SOLV)
AMED vs SOLV Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SOLV has a market cap of 13.5B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while SOLV trades at $78.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SOLV's P/E ratio is 12.50. In terms of profitability, AMED's ROE is +0.11%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, AMED is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for AMED.Check SOLV's competition here
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)
AMED vs FMS Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, FMS has a market cap of 13.2B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while FMS trades at $24.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas FMS's P/E ratio is 9.76. In terms of profitability, AMED's ROE is +0.11%, compared to FMS's ROE of +0.07%. Regarding short-term risk, AMED is less volatile compared to FMS. This indicates lower risk in terms of short-term price fluctuations for AMED.Check FMS's competition here
Encompass Health Corporation (NYSE: EHC)
AMED vs EHC Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, EHC has a market cap of 11.2B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while EHC trades at $112.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas EHC's P/E ratio is 19.83. In terms of profitability, AMED's ROE is +0.11%, compared to EHC's ROE of +0.25%. Regarding short-term risk, AMED is less volatile compared to EHC. This indicates lower risk in terms of short-term price fluctuations for AMED.Check EHC's competition here
The Ensign Group, Inc. (NASDAQ: ENSG)
AMED vs ENSG Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ENSG has a market cap of 10.1B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while ENSG trades at $172.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ENSG's P/E ratio is 25.07. In terms of profitability, AMED's ROE is +0.11%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, AMED is less volatile compared to ENSG. This indicates lower risk in terms of short-term price fluctuations for AMED.Check ENSG's competition here
Universal Health Services, Inc. (NYSE: UHS)
AMED vs UHS Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, UHS has a market cap of 9.8B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while UHS trades at $155.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas UHS's P/E ratio is 6.91. In terms of profitability, AMED's ROE is +0.11%, compared to UHS's ROE of +0.21%. Regarding short-term risk, AMED is less volatile compared to UHS. This indicates lower risk in terms of short-term price fluctuations for AMED.Check UHS's competition here
Oak Street Health, Inc. (NYSE: OSH)
AMED vs OSH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas OSH's P/E ratio is -17.65. In terms of profitability, AMED's ROE is +0.11%, compared to OSH's ROE of +4.64%. Regarding short-term risk, AMED is more volatile compared to OSH. This indicates higher risk in terms of short-term price fluctuations for AMED.Check OSH's competition here
PACS Group, Inc. (NYSE: PACS)
AMED vs PACS Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, PACS has a market cap of 7.4B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while PACS trades at $46.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas PACS's P/E ratio is 39.80. In terms of profitability, AMED's ROE is +0.11%, compared to PACS's ROE of +0.27%. Regarding short-term risk, AMED is less volatile compared to PACS. This indicates lower risk in terms of short-term price fluctuations for AMED.Check PACS's competition here
Chemed Corporation (NYSE: CHE)
AMED vs CHE Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CHE has a market cap of 6.8B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while CHE trades at $511.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CHE's P/E ratio is 23.66. In terms of profitability, AMED's ROE is +0.11%, compared to CHE's ROE of +0.25%. Regarding short-term risk, AMED is less volatile compared to CHE. This indicates lower risk in terms of short-term price fluctuations for AMED.Check CHE's competition here
LHC Group, Inc. (NASDAQ: LHCG)
AMED vs LHCG Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas LHCG's P/E ratio is 82.83. In terms of profitability, AMED's ROE is +0.11%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, AMED is less volatile compared to LHCG. This indicates lower risk in terms of short-term price fluctuations for AMED.Check LHCG's competition here
LifeStance Health Group, Inc. (NASDAQ: LFST)
AMED vs LFST Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, LFST has a market cap of 4.2B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while LFST trades at $10.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas LFST's P/E ratio is 173.65. In terms of profitability, AMED's ROE is +0.11%, compared to LFST's ROE of +0.02%. Regarding short-term risk, AMED is less volatile compared to LFST. This indicates lower risk in terms of short-term price fluctuations for AMED.Check LFST's competition here
Concentra Group Holdings Parent, Inc. (NYSE: CON)
AMED vs CON Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CON has a market cap of 4B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while CON trades at $31.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CON's P/E ratio is 21.95. In terms of profitability, AMED's ROE is +0.11%, compared to CON's ROE of +0.46%. Regarding short-term risk, AMED is less volatile compared to CON. This indicates lower risk in terms of short-term price fluctuations for AMED.Check CON's competition here
Brookdale Senior Living Inc. (NYSE: BKD)
AMED vs BKD Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, BKD has a market cap of 3.6B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while BKD trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas BKD's P/E ratio is -26.11. In terms of profitability, AMED's ROE is +0.11%, compared to BKD's ROE of +401.19%. Regarding short-term risk, AMED is less volatile compared to BKD. This indicates lower risk in terms of short-term price fluctuations for AMED.Check BKD's competition here
National HealthCare Corporation (AMEX: NHC)
AMED vs NHC Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NHC has a market cap of 3.5B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while NHC trades at $225.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NHC's P/E ratio is 32.32. In terms of profitability, AMED's ROE is +0.11%, compared to NHC's ROE of +0.12%. Regarding short-term risk, AMED is less volatile compared to NHC. This indicates lower risk in terms of short-term price fluctuations for AMED.Check NHC's competition here
Option Care Health, Inc. (NASDAQ: OPCH)
AMED vs OPCH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, OPCH has a market cap of 3.4B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while OPCH trades at $21.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas OPCH's P/E ratio is 12.59. In terms of profitability, AMED's ROE is +0.11%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, AMED is less volatile compared to OPCH. This indicates lower risk in terms of short-term price fluctuations for AMED.Check OPCH's competition here
Acadia Healthcare Company, Inc. (NASDAQ: ACHC)
AMED vs ACHC Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ACHC has a market cap of 3.2B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while ACHC trades at $34.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ACHC's P/E ratio is 17.34. In terms of profitability, AMED's ROE is +0.11%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, AMED is less volatile compared to ACHC. This indicates lower risk in terms of short-term price fluctuations for AMED.Check ACHC's competition here
Pediatrix Medical Group, Inc. (NYSE: MD)
AMED vs MD Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, MD has a market cap of 2.2B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while MD trades at $26.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas MD's P/E ratio is 12.27. In terms of profitability, AMED's ROE is +0.11%, compared to MD's ROE of +0.20%. Regarding short-term risk, AMED is less volatile compared to MD. This indicates lower risk in terms of short-term price fluctuations for AMED.Check MD's competition here
Addus HomeCare Corporation (NASDAQ: ADUS)
AMED vs ADUS Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ADUS has a market cap of 2.1B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while ADUS trades at $114.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ADUS's P/E ratio is 17.79. In terms of profitability, AMED's ROE is +0.11%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, AMED is less volatile compared to ADUS. This indicates lower risk in terms of short-term price fluctuations for AMED.Check ADUS's competition here
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH)
AMED vs AVAH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AVAH has a market cap of 2.1B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AVAH trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AVAH's P/E ratio is 13.90. In terms of profitability, AMED's ROE is +0.11%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, AMED is less volatile compared to AVAH. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AVAH's competition here
Surgery Partners, Inc. (NASDAQ: SGRY)
AMED vs SGRY Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SGRY has a market cap of 2.1B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while SGRY trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SGRY's P/E ratio is 40.33. In terms of profitability, AMED's ROE is +0.11%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, AMED is less volatile compared to SGRY. This indicates lower risk in terms of short-term price fluctuations for AMED.Check SGRY's competition here
Select Medical Holdings Corporation (NYSE: SEM)
AMED vs SEM Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while SEM trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SEM's P/E ratio is 15.43. In terms of profitability, AMED's ROE is +0.11%, compared to SEM's ROE of +0.08%. Regarding short-term risk, AMED is less volatile compared to SEM. This indicates lower risk in terms of short-term price fluctuations for AMED.Check SEM's competition here
Astrana Health, Inc. (NASDAQ: ASTH)
AMED vs ASTH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ASTH has a market cap of 2B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while ASTH trades at $40.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ASTH's P/E ratio is 27.24. In terms of profitability, AMED's ROE is +0.11%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, AMED is less volatile compared to ASTH. This indicates lower risk in terms of short-term price fluctuations for AMED.Check ASTH's competition here
Apollo Medical Holdings, Inc. (NASDAQ: AMEH)
AMED vs AMEH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AMEH's P/E ratio is 39.25. In terms of profitability, AMED's ROE is +0.11%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, AMED is less volatile compared to AMEH. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AMEH's competition here
Agilon Health, Inc. (NYSE: AGL)
AMED vs AGL Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AGL trades at $98.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AGL's P/E ratio is -9.57. In terms of profitability, AMED's ROE is +0.11%, compared to AGL's ROE of -1.46%. Regarding short-term risk, AMED is less volatile compared to AGL. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AGL's competition here
Innovage Holding Corp. (NASDAQ: INNV)
AMED vs INNV Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, INNV has a market cap of 1.6B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while INNV trades at $11.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas INNV's P/E ratio is -128.44. In terms of profitability, AMED's ROE is +0.11%, compared to INNV's ROE of -0.09%. Regarding short-term risk, AMED is less volatile compared to INNV. This indicates lower risk in terms of short-term price fluctuations for AMED.Check INNV's competition here
Healthcare Services Group, Inc. (NASDAQ: HCSG)
AMED vs HCSG Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, HCSG has a market cap of 1.6B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while HCSG trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas HCSG's P/E ratio is 18.19. In terms of profitability, AMED's ROE is +0.11%, compared to HCSG's ROE of +0.23%. Regarding short-term risk, AMED is less volatile compared to HCSG. This indicates lower risk in terms of short-term price fluctuations for AMED.Check HCSG's competition here
Ardent Health Inc. (NYSE: ARDT)
AMED vs ARDT Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ARDT has a market cap of 1.5B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while ARDT trades at $10.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ARDT's P/E ratio is 6.47. In terms of profitability, AMED's ROE is +0.11%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, AMED is less volatile compared to ARDT. This indicates lower risk in terms of short-term price fluctuations for AMED.Check ARDT's competition here
The Pennant Group, Inc. (NASDAQ: PNTG)
AMED vs PNTG Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, PNTG has a market cap of 1.4B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while PNTG trades at $41.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas PNTG's P/E ratio is 33.46. In terms of profitability, AMED's ROE is +0.11%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, AMED is less volatile compared to PNTG. This indicates lower risk in terms of short-term price fluctuations for AMED.Check PNTG's competition here
AMN Healthcare Services, Inc. (NYSE: AMN)
AMED vs AMN Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AMN has a market cap of 1.3B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AMN trades at $32.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AMN's P/E ratio is 10.93. In terms of profitability, AMED's ROE is +0.11%, compared to AMN's ROE of -0.05%. Regarding short-term risk, AMED is less volatile compared to AMN. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AMN's competition here
Brookdale Senior Living Inc. 7. (NYSE: BKDT)
AMED vs BKDT Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas BKDT's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, AMED is more volatile compared to BKDT. This indicates higher risk in terms of short-term price fluctuations for AMED.Check BKDT's competition here
U.S. Physical Therapy, Inc. (NYSE: USPH)
AMED vs USPH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, USPH has a market cap of 1.1B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while USPH trades at $74.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas USPH's P/E ratio is 28.74. In terms of profitability, AMED's ROE is +0.11%, compared to USPH's ROE of +0.00%. Regarding short-term risk, AMED is less volatile compared to USPH. This indicates lower risk in terms of short-term price fluctuations for AMED.Check USPH's competition here
COMPASS Pathways plc (NASDAQ: CMPS)
AMED vs CMPS Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CMPS has a market cap of 1.1B. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while CMPS trades at $11.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CMPS's P/E ratio is -5.49. In terms of profitability, AMED's ROE is +0.11%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, AMED is less volatile compared to CMPS. This indicates lower risk in terms of short-term price fluctuations for AMED.Check CMPS's competition here
Fidelity Select Health Care Svcs Port (NASDAQ: FSHCX)
AMED vs FSHCX Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, FSHCX has a market cap of 882M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while FSHCX trades at $120.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas FSHCX's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to FSHCX's ROE of N/A. Regarding short-term risk, AMED is more volatile compared to FSHCX. This indicates higher risk in terms of short-term price fluctuations for AMED.Check FSHCX's competition here
Talkspace, Inc. (NASDAQ: TALKW)
AMED vs TALKW Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TALKW has a market cap of 874.4M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TALKW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, AMED is less volatile compared to TALKW. This indicates lower risk in terms of short-term price fluctuations for AMED.Check TALKW's competition here
Talkspace, Inc. (NASDAQ: TALK)
AMED vs TALK Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TALK has a market cap of 872.7M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while TALK trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TALK's P/E ratio is 768.44. In terms of profitability, AMED's ROE is +0.11%, compared to TALK's ROE of +0.01%. Regarding short-term risk, AMED is less volatile compared to TALK. This indicates lower risk in terms of short-term price fluctuations for AMED.Check TALK's competition here
Nutex Health, Inc. (NASDAQ: NUTX)
AMED vs NUTX Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NUTX has a market cap of 868.6M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while NUTX trades at $145.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NUTX's P/E ratio is 11.27. In terms of profitability, AMED's ROE is +0.11%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, AMED is less volatile compared to NUTX. This indicates lower risk in terms of short-term price fluctuations for AMED.Check NUTX's competition here
Sonida Senior Living, Inc. (NYSE: SNDA)
AMED vs SNDA Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SNDA has a market cap of 833.8M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while SNDA trades at $41.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SNDA's P/E ratio is -7.72. In terms of profitability, AMED's ROE is +0.11%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, AMED is less volatile compared to SNDA. This indicates lower risk in terms of short-term price fluctuations for AMED.Check SNDA's competition here
Enhabit, Inc. (NYSE: EHAB)
AMED vs EHAB Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas EHAB's P/E ratio is -197.14. In terms of profitability, AMED's ROE is +0.11%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, AMED is less volatile compared to EHAB. This indicates lower risk in terms of short-term price fluctuations for AMED.Check EHAB's competition here
GMR Solutions Inc. (NYSE: GMRS)
AMED vs GMRS Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, GMRS has a market cap of 594M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while GMRS trades at $12.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas GMRS's P/E ratio is 5.76. In terms of profitability, AMED's ROE is +0.11%, compared to GMRS's ROE of +1.01%. Regarding short-term risk, AMED is less volatile compared to GMRS. This indicates lower risk in terms of short-term price fluctuations for AMED.Check GMRS's competition here
The Oncology Institute, Inc. (NASDAQ: TOI)
AMED vs TOI Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TOI has a market cap of 497.9M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while TOI trades at $4.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TOI's P/E ratio is -13.83. In terms of profitability, AMED's ROE is +0.11%, compared to TOI's ROE of +3.27%. Regarding short-term risk, AMED is less volatile compared to TOI. This indicates lower risk in terms of short-term price fluctuations for AMED.Check TOI's competition here
Viemed Healthcare, Inc. (NASDAQ: VMD)
AMED vs VMD Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, VMD has a market cap of 451.2M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while VMD trades at $11.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas VMD's P/E ratio is 31.81. In terms of profitability, AMED's ROE is +0.11%, compared to VMD's ROE of +0.11%. Regarding short-term risk, AMED is less volatile compared to VMD. This indicates lower risk in terms of short-term price fluctuations for AMED.Check VMD's competition here
Charming Medical Limited Class A Ordinary Shares (NASDAQ: MCTA)
AMED vs MCTA Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas MCTA's P/E ratio is 419.36. In terms of profitability, AMED's ROE is +0.11%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, AMED is more volatile compared to MCTA. This indicates higher risk in terms of short-term price fluctuations for AMED.Check MCTA's competition here
Strata Critical Medical, Inc. (NASDAQ: SRTA)
AMED vs SRTA Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SRTA has a market cap of 436.1M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while SRTA trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SRTA's P/E ratio is -35.46. In terms of profitability, AMED's ROE is +0.11%, compared to SRTA's ROE of +0.18%. Regarding short-term risk, AMED is less volatile compared to SRTA. This indicates lower risk in terms of short-term price fluctuations for AMED.Check SRTA's competition here
The Oncology Institute, Inc. (NASDAQ: TOIIW)
AMED vs TOIIW Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TOIIW has a market cap of 388.9M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TOIIW's P/E ratio is -0.18. In terms of profitability, AMED's ROE is +0.11%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, AMED is less volatile compared to TOIIW. This indicates lower risk in terms of short-term price fluctuations for AMED.Check TOIIW's competition here
Community Health Systems, Inc. (NYSE: CYH)
AMED vs CYH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CYH has a market cap of 384M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while CYH trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CYH's P/E ratio is 3.73. In terms of profitability, AMED's ROE is +0.11%, compared to CYH's ROE of +0.21%. Regarding short-term risk, AMED is less volatile compared to CYH. This indicates lower risk in terms of short-term price fluctuations for AMED.Check CYH's competition here
Auna S.A. (NYSE: AUNA)
AMED vs AUNA Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AUNA has a market cap of 373.8M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AUNA trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AUNA's P/E ratio is 4.55. In terms of profitability, AMED's ROE is +0.11%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, AMED is less volatile compared to AUNA. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AUNA's competition here
AirSculpt Technologies, Inc. (NASDAQ: AIRS)
AMED vs AIRS Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AIRS has a market cap of 325.2M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AIRS trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AIRS's P/E ratio is -153.67. In terms of profitability, AMED's ROE is +0.11%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, AMED is less volatile compared to AIRS. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AIRS's competition here
Capital Senior Living Corporation (NYSE: CSU)
AMED vs CSU Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CSU's P/E ratio is 0.67. In terms of profitability, AMED's ROE is +0.11%, compared to CSU's ROE of -0.51%. Regarding short-term risk, AMED is less volatile compared to CSU. This indicates lower risk in terms of short-term price fluctuations for AMED.Check CSU's competition here
The Joint Corp. (NASDAQ: JYNT)
AMED vs JYNT Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, JYNT has a market cap of 119M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while JYNT trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas JYNT's P/E ratio is 83.50. In terms of profitability, AMED's ROE is +0.11%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, AMED is less volatile compared to JYNT. This indicates lower risk in terms of short-term price fluctuations for AMED.Check JYNT's competition here
biote Corp. (NASDAQ: BTMD)
AMED vs BTMD Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, BTMD has a market cap of 100.6M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while BTMD trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas BTMD's P/E ratio is 5.18. In terms of profitability, AMED's ROE is +0.11%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, AMED is less volatile compared to BTMD. This indicates lower risk in terms of short-term price fluctuations for AMED.Check BTMD's competition here
Five Star Senior Living Inc. (NASDAQ: FVE)
AMED vs FVE Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas FVE's P/E ratio is -5.64. In terms of profitability, AMED's ROE is +0.11%, compared to FVE's ROE of -0.15%. Regarding short-term risk, AMED is less volatile compared to FVE. This indicates lower risk in terms of short-term price fluctuations for AMED.Check FVE's competition here
Kindly MD, Inc. (NASDAQ: KDLYW)
AMED vs KDLYW Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas KDLYW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, AMED is less volatile compared to KDLYW. This indicates lower risk in terms of short-term price fluctuations for AMED.Check KDLYW's competition here
DocGo Inc. (NASDAQ: DCGO)
AMED vs DCGO Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, DCGO has a market cap of 58.9M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while DCGO trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas DCGO's P/E ratio is -0.68. In terms of profitability, AMED's ROE is +0.11%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, AMED is less volatile compared to DCGO. This indicates lower risk in terms of short-term price fluctuations for AMED.Check DCGO's competition here
AlerisLife Inc. (NASDAQ: ALR)
AMED vs ALR Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ALR's P/E ratio is -1.11. In terms of profitability, AMED's ROE is +0.11%, compared to ALR's ROE of -0.15%. Regarding short-term risk, AMED is less volatile compared to ALR. This indicates lower risk in terms of short-term price fluctuations for AMED.Check ALR's competition here
Park Dental Partners, Inc. Common Stock (NASDAQ: PARK)
AMED vs PARK Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, PARK has a market cap of 36.5M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while PARK trades at $18.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas PARK's P/E ratio is 25.36. In terms of profitability, AMED's ROE is +0.11%, compared to PARK's ROE of -0.24%. Regarding short-term risk, AMED is less volatile compared to PARK. This indicates lower risk in terms of short-term price fluctuations for AMED.Check PARK's competition here
IMAC Holdings, Inc. (NASDAQ: IMAC)
AMED vs IMAC Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas IMAC's P/E ratio is -2.27. In terms of profitability, AMED's ROE is +0.11%, compared to IMAC's ROE of +0.00%. Regarding short-term risk, AMED is less volatile compared to IMAC. This indicates lower risk in terms of short-term price fluctuations for AMED.Check IMAC's competition here
P3 Health Partners Inc. (NASDAQ: PIII)
AMED vs PIII Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, PIII has a market cap of 31.5M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while PIII trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas PIII's P/E ratio is -0.24. In terms of profitability, AMED's ROE is +0.11%, compared to PIII's ROE of +1.85%. Regarding short-term risk, AMED is less volatile compared to PIII. This indicates lower risk in terms of short-term price fluctuations for AMED.Check PIII's competition here
Cryo-Cell International, Inc. (AMEX: CCEL)
AMED vs CCEL Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CCEL has a market cap of 28.1M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while CCEL trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CCEL's P/E ratio is -10.55. In terms of profitability, AMED's ROE is +0.11%, compared to CCEL's ROE of +0.14%. Regarding short-term risk, AMED is less volatile compared to CCEL. This indicates lower risk in terms of short-term price fluctuations for AMED.Check CCEL's competition here
Cano Health, Inc. (NYSE: CANO-WT)
AMED vs CANO-WT Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, AMED is less volatile compared to CANO-WT. This indicates lower risk in terms of short-term price fluctuations for AMED.Check CANO-WT's competition here
Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH)
AMED vs AIH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AIH's P/E ratio is -2.78. In terms of profitability, AMED's ROE is +0.11%, compared to AIH's ROE of +1.16%. Regarding short-term risk, AMED is less volatile compared to AIH. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AIH's competition here
Cano Health, Inc. (NYSE: CANO)
AMED vs CANO Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CANO's P/E ratio is -0.01. In terms of profitability, AMED's ROE is +0.11%, compared to CANO's ROE of -1.49%. Regarding short-term risk, AMED is less volatile compared to CANO. This indicates lower risk in terms of short-term price fluctuations for AMED.Check CANO's competition here
Avem Health Partners, Inc. (NYSE: FPCG)
AMED vs FPCG Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas FPCG's P/E ratio is 0.09. In terms of profitability, AMED's ROE is +0.11%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, AMED is more volatile compared to FPCG. This indicates higher risk in terms of short-term price fluctuations for AMED.Check FPCG's competition here
Field Trip Health Ltd. (NASDAQ: FTRP)
AMED vs FTRP Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas FTRP's P/E ratio is -1.22. In terms of profitability, AMED's ROE is +0.11%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, AMED is less volatile compared to FTRP. This indicates lower risk in terms of short-term price fluctuations for AMED.Check FTRP's competition here
American Shared Hospital Services (AMEX: AMS)
AMED vs AMS Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AMS has a market cap of 9.5M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AMS trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AMS's P/E ratio is -6.47. In terms of profitability, AMED's ROE is +0.11%, compared to AMS's ROE of -0.06%. Regarding short-term risk, AMED is less volatile compared to AMS. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AMS's competition here
Basel Medical Group Ltd Ordinary Shares (NASDAQ: BMGL)
AMED vs BMGL Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, BMGL has a market cap of 9.2M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while BMGL trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas BMGL's P/E ratio is -1.11. In terms of profitability, AMED's ROE is +0.11%, compared to BMGL's ROE of -1.74%. Regarding short-term risk, AMED is less volatile compared to BMGL. This indicates lower risk in terms of short-term price fluctuations for AMED.Check BMGL's competition here
XWELL, Inc. (NASDAQ: XWEL)
AMED vs XWEL Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, XWEL has a market cap of 6.4M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while XWEL trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas XWEL's P/E ratio is -0.32. In terms of profitability, AMED's ROE is +0.11%, compared to XWEL's ROE of +2.89%. Regarding short-term risk, AMED is less volatile compared to XWEL. This indicates lower risk in terms of short-term price fluctuations for AMED.Check XWEL's competition here
ModivCare Inc. (NASDAQ: MODV)
AMED vs MODV Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas MODV's P/E ratio is -0.06. In terms of profitability, AMED's ROE is +0.11%, compared to MODV's ROE of +1.36%. Regarding short-term risk, AMED is more volatile compared to MODV. This indicates higher risk in terms of short-term price fluctuations for AMED.Check MODV's competition here
Greenbrook TMS Inc. (NASDAQ: GBNH)
AMED vs GBNH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas GBNH's P/E ratio is -0.06. In terms of profitability, AMED's ROE is +0.11%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, AMED is less volatile compared to GBNH. This indicates lower risk in terms of short-term price fluctuations for AMED.Check GBNH's competition here
Regional Health Properties, Inc. (AMEX: RHE-PA)
AMED vs RHE-PA Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, AMED's ROE is +0.11%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, AMED is less volatile compared to RHE-PA. This indicates lower risk in terms of short-term price fluctuations for AMED.Check RHE-PA's competition here
Regional Health Properties, Inc. (AMEX: RHE)
AMED vs RHE Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas RHE's P/E ratio is -1.79. In terms of profitability, AMED's ROE is +0.11%, compared to RHE's ROE of -0.36%. Regarding short-term risk, AMED is less volatile compared to RHE. This indicates lower risk in terms of short-term price fluctuations for AMED.Check RHE's competition here
20/20 Biolabs Inc. (NASDAQ: AIDX)
AMED vs AIDX Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AIDX has a market cap of 2.8M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AIDX trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AIDX's P/E ratio is -0.93. In terms of profitability, AMED's ROE is +0.11%, compared to AIDX's ROE of +0.79%. Regarding short-term risk, AMED is less volatile compared to AIDX. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AIDX's competition here
IMAC Holdings, Inc. (NASDAQ: IMACW)
AMED vs IMACW Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas IMACW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to IMACW's ROE of +0.73%. Regarding short-term risk, AMED is less volatile compared to IMACW. This indicates lower risk in terms of short-term price fluctuations for AMED.Check IMACW's competition here
Nakamoto Inc. (NASDAQ: NAKAW)
AMED vs NAKAW Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NAKAW has a market cap of 1.5M. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while NAKAW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NAKAW's P/E ratio is -0.53. In terms of profitability, AMED's ROE is +0.11%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, AMED is more volatile compared to NAKAW. This indicates higher risk in terms of short-term price fluctuations for AMED.Check NAKAW's competition here
Concord Medical Services Holdings Limited (NYSE: CCM)
AMED vs CCM Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CCM has a market cap of 626.1K. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while CCM trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CCM's P/E ratio is -0.29. In terms of profitability, AMED's ROE is +0.11%, compared to CCM's ROE of +0.06%. Regarding short-term risk, AMED is less volatile compared to CCM. This indicates lower risk in terms of short-term price fluctuations for AMED.Check CCM's competition here
NewGenIvf Group Limited (NASDAQ: NIVF)
AMED vs NIVF Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NIVF has a market cap of 212.3K. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while NIVF trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NIVF's P/E ratio is 0.55. In terms of profitability, AMED's ROE is +0.11%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, AMED is less volatile compared to NIVF. This indicates lower risk in terms of short-term price fluctuations for AMED.Check NIVF's competition here
Mobile-health Network Solutions Class A Ordinary Shares (NASDAQ: MNDR)
AMED vs MNDR Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, MNDR has a market cap of 53.6K. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while MNDR trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas MNDR's P/E ratio is -0.05. In terms of profitability, AMED's ROE is +0.11%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, AMED is less volatile compared to MNDR. This indicates lower risk in terms of short-term price fluctuations for AMED.Check MNDR's competition here
NewGenIvf Group Limited (NASDAQ: NIVFW)
AMED vs NIVFW Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NIVFW has a market cap of 50K. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NIVFW's P/E ratio is -0.01. In terms of profitability, AMED's ROE is +0.11%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, AMED is less volatile compared to NIVFW. This indicates lower risk in terms of short-term price fluctuations for AMED.Check NIVFW's competition here
DocGo Inc. (NASDAQ: DCGOW)
AMED vs DCGOW Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas DCGOW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, AMED is less volatile compared to DCGOW. This indicates lower risk in terms of short-term price fluctuations for AMED.Check DCGOW's competition here
SOC Telemed, Inc. (NASDAQ: TLMDW)
AMED vs TLMDW Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TLMDW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, AMED is less volatile compared to TLMDW. This indicates lower risk in terms of short-term price fluctuations for AMED.Check TLMDW's competition here
Hanger, Inc. (NYSE: HNGR)
AMED vs HNGR Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas HNGR's P/E ratio is 19.71. In terms of profitability, AMED's ROE is +0.11%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, AMED is less volatile compared to HNGR. This indicates lower risk in terms of short-term price fluctuations for AMED.Check HNGR's competition here
ATI Physical Therapy, Inc. (NYSE: ATIP-WT)
AMED vs ATIP-WT Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, AMED is less volatile compared to ATIP-WT. This indicates lower risk in terms of short-term price fluctuations for AMED.Check ATIP-WT's competition here
Tivity Health, Inc. (NASDAQ: TVTY)
AMED vs TVTY Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TVTY's P/E ratio is 19.06. In terms of profitability, AMED's ROE is +0.11%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, AMED is more volatile compared to TVTY. This indicates higher risk in terms of short-term price fluctuations for AMED.Check TVTY's competition here
New Frontier Health Corporation (NYSE: NFH)
AMED vs NFH Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NFH has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NFH's P/E ratio is -19.75. In terms of profitability, AMED's ROE is +0.11%, compared to NFH's ROE of -0.06%. Regarding short-term risk, AMED is less volatile compared to NFH. This indicates lower risk in terms of short-term price fluctuations for AMED.Check NFH's competition here
Skylight Health Group Inc. (NASDAQ: SLHGP)
AMED vs SLHGP Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, AMED's ROE is +0.11%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, AMED is more volatile compared to SLHGP. This indicates higher risk in terms of short-term price fluctuations for AMED.Check SLHGP's competition here
Skylight Health Group Inc. (NASDAQ: SLHG)
AMED vs SLHG Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SLHG's P/E ratio is -1.48. In terms of profitability, AMED's ROE is +0.11%, compared to SLHG's ROE of N/A. Regarding short-term risk, AMED is less volatile compared to SLHG. This indicates lower risk in terms of short-term price fluctuations for AMED.Check SLHG's competition here
Diversicare Healthcare Services, Inc. (NASDAQ: DVCR)
AMED vs DVCR Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas DVCR's P/E ratio is 28.34. In terms of profitability, AMED's ROE is +0.11%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, AMED is less volatile compared to DVCR. This indicates lower risk in terms of short-term price fluctuations for AMED.Check DVCR's competition here
Almost Family Inc. (NASDAQ: AFAM)
AMED vs AFAM Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AFAM's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.11%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, AMED is less volatile compared to AFAM. This indicates lower risk in terms of short-term price fluctuations for AMED.Check AFAM's competition here
SOC Telemed, Inc. (NASDAQ: TLMD)
AMED vs TLMD Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TLMD's P/E ratio is -1.60. In terms of profitability, AMED's ROE is +0.11%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, AMED is less volatile compared to TLMD. This indicates lower risk in terms of short-term price fluctuations for AMED.Check TLMD's competition here
Kindred Healthcare, Inc. (NYSE: KND)
AMED vs KND Comparison July 2026
Amedisys, Inc. (NASDAQ: AMED) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, KND has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99 on the NASDAQ, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas KND's P/E ratio is -1.14. In terms of profitability, AMED's ROE is +0.11%, compared to KND's ROE of -0.53%. Regarding short-term risk, AMED is less volatile compared to KND. This indicates lower risk in terms of short-term price fluctuations for AMED.Check KND's competition here